Atypical movement disorders in antiphospholipid syndrome.
Identifieur interne : 002D33 ( PubMed/Curation ); précédent : 002D32; suivant : 002D34Atypical movement disorders in antiphospholipid syndrome.
Auteurs : Davide Martino [Royaume-Uni] ; Nee-Kong Chew ; Pablo Mir ; Mark J. Edwards ; Niall P. Quinn ; Kailash P. BhatiaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Adolescent, Antiphospholipid Syndrome (diagnosis), Antiphospholipid Syndrome (drug therapy), Antiphospholipid Syndrome (physiopathology), Brain (pathology), Brain (physiopathology), Cerebral Infarction (diagnosis), Cerebral Infarction (drug therapy), Cerebral Infarction (physiopathology), Diagnosis, Differential, Dyskinesias (diagnosis), Dyskinesias (drug therapy), Dyskinesias (physiopathology), Electroencephalography (drug effects), Electromyography (drug effects), Female, Follow-Up Studies, Frontal Lobe (pathology), Frontal Lobe (physiopathology), Humans, Lupus Erythematosus, Systemic (diagnosis), Lupus Erythematosus, Systemic (drug therapy), Lupus Erythematosus, Systemic (physiopathology), Magnetic Resonance Imaging, Middle Aged, Movement Disorders (diagnosis), Movement Disorders (drug therapy), Movement Disorders (physiopathology), Myoclonus (diagnosis), Myoclonus (drug therapy), Myoclonus (physiopathology), Neurologic Examination (drug effects), Neuropsychological Tests, Occipital Lobe (pathology), Occipital Lobe (physiopathology), Phenindione (therapeutic use), Phenprocoumon (therapeutic use), Sneddon Syndrome (diagnosis), Sneddon Syndrome (drug therapy), Sneddon Syndrome (physiopathology), Spinocerebellar Degenerations (diagnosis), Spinocerebellar Degenerations (drug therapy), Spinocerebellar Degenerations (physiopathology), Tics (diagnosis), Tics (drug therapy), Tics (physiopathology), Tourette Syndrome (diagnosis), Tourette Syndrome (drug therapy), Tourette Syndrome (physiopathology), Tremor (diagnosis), Tremor (drug therapy), Tremor (physiopathology), Warfarin (therapeutic use).
- MESH :
- chemical , therapeutic use : Phenindione, Phenprocoumon, Warfarin.
- diagnosis : Antiphospholipid Syndrome, Cerebral Infarction, Dyskinesias, Lupus Erythematosus, Systemic, Movement Disorders, Myoclonus, Sneddon Syndrome, Spinocerebellar Degenerations, Tics, Tourette Syndrome, Tremor.
- drug effects : Electroencephalography, Electromyography, Neurologic Examination.
- drug therapy : Antiphospholipid Syndrome, Cerebral Infarction, Dyskinesias, Lupus Erythematosus, Systemic, Movement Disorders, Myoclonus, Sneddon Syndrome, Spinocerebellar Degenerations, Tics, Tourette Syndrome, Tremor.
- pathology : Brain, Frontal Lobe, Occipital Lobe.
- physiopathology : Antiphospholipid Syndrome, Brain, Cerebral Infarction, Dyskinesias, Frontal Lobe, Lupus Erythematosus, Systemic, Movement Disorders, Myoclonus, Occipital Lobe, Sneddon Syndrome, Spinocerebellar Degenerations, Tics, Tourette Syndrome, Tremor.
- Adolescent, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Middle Aged, Neuropsychological Tests.
Abstract
Movement disorders have only rarely been reported in association with antiphospholipid syndrome (APS). In such cases, chorea is the most common disorder observed, with occasional reports of hemidystonia, Parkinsonism, and hemiballism. We report here on 3 cases of APS (3 women ages 16, 46, and 56 years) who presented with movement disorders, including tics, tremor, myoclonus, and a corticobasal syndrome, never or rarely reported in association with this disease. Mild executive dysfunction was observed in all 3 patients. We also report the successful treatment of two of these patients with mild oral anticoagulation (INR 2-3). Movement disorders in APS seem more clinically heterogeneous than previously thought. Oral anticoagulation should be considered in the treatment of movement disorders associated with APS.
DOI: 10.1002/mds.20842
PubMed: 16538618
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D33
Links to Exploration step
pubmed:16538618Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atypical movement disorders in antiphospholipid syndrome.</title><author><name sortKey="Martino, Davide" sort="Martino, Davide" uniqKey="Martino D" first="Davide" last="Martino">Davide Martino</name><affiliation wicri:level="1"><nlm:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Chew, Nee Kong" sort="Chew, Nee Kong" uniqKey="Chew N" first="Nee-Kong" last="Chew">Nee-Kong Chew</name></author><author><name sortKey="Mir, Pablo" sort="Mir, Pablo" uniqKey="Mir P" first="Pablo" last="Mir">Pablo Mir</name></author><author><name sortKey="Edwards, Mark J" sort="Edwards, Mark J" uniqKey="Edwards M" first="Mark J" last="Edwards">Mark J. Edwards</name></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P" last="Quinn">Niall P. Quinn</name></author><author><name sortKey="Bhatia, Kailash P" sort="Bhatia, Kailash P" uniqKey="Bhatia K" first="Kailash P" last="Bhatia">Kailash P. Bhatia</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20842</idno><idno type="RBID">pubmed:16538618</idno><idno type="pmid">16538618</idno><idno type="wicri:Area/PubMed/Corpus">002D33</idno><idno type="wicri:Area/PubMed/Curation">002D33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Atypical movement disorders in antiphospholipid syndrome.</title><author><name sortKey="Martino, Davide" sort="Martino, Davide" uniqKey="Martino D" first="Davide" last="Martino">Davide Martino</name><affiliation wicri:level="1"><nlm:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Chew, Nee Kong" sort="Chew, Nee Kong" uniqKey="Chew N" first="Nee-Kong" last="Chew">Nee-Kong Chew</name></author><author><name sortKey="Mir, Pablo" sort="Mir, Pablo" uniqKey="Mir P" first="Pablo" last="Mir">Pablo Mir</name></author><author><name sortKey="Edwards, Mark J" sort="Edwards, Mark J" uniqKey="Edwards M" first="Mark J" last="Edwards">Mark J. Edwards</name></author><author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P" last="Quinn">Niall P. Quinn</name></author><author><name sortKey="Bhatia, Kailash P" sort="Bhatia, Kailash P" uniqKey="Bhatia K" first="Kailash P" last="Bhatia">Kailash P. Bhatia</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Antiphospholipid Syndrome (diagnosis)</term><term>Antiphospholipid Syndrome (drug therapy)</term><term>Antiphospholipid Syndrome (physiopathology)</term><term>Brain (pathology)</term><term>Brain (physiopathology)</term><term>Cerebral Infarction (diagnosis)</term><term>Cerebral Infarction (drug therapy)</term><term>Cerebral Infarction (physiopathology)</term><term>Diagnosis, Differential</term><term>Dyskinesias (diagnosis)</term><term>Dyskinesias (drug therapy)</term><term>Dyskinesias (physiopathology)</term><term>Electroencephalography (drug effects)</term><term>Electromyography (drug effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Frontal Lobe (pathology)</term><term>Frontal Lobe (physiopathology)</term><term>Humans</term><term>Lupus Erythematosus, Systemic (diagnosis)</term><term>Lupus Erythematosus, Systemic (drug therapy)</term><term>Lupus Erythematosus, Systemic (physiopathology)</term><term>Magnetic Resonance Imaging</term><term>Middle Aged</term><term>Movement Disorders (diagnosis)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (physiopathology)</term><term>Myoclonus (diagnosis)</term><term>Myoclonus (drug therapy)</term><term>Myoclonus (physiopathology)</term><term>Neurologic Examination (drug effects)</term><term>Neuropsychological Tests</term><term>Occipital Lobe (pathology)</term><term>Occipital Lobe (physiopathology)</term><term>Phenindione (therapeutic use)</term><term>Phenprocoumon (therapeutic use)</term><term>Sneddon Syndrome (diagnosis)</term><term>Sneddon Syndrome (drug therapy)</term><term>Sneddon Syndrome (physiopathology)</term><term>Spinocerebellar Degenerations (diagnosis)</term><term>Spinocerebellar Degenerations (drug therapy)</term><term>Spinocerebellar Degenerations (physiopathology)</term><term>Tics (diagnosis)</term><term>Tics (drug therapy)</term><term>Tics (physiopathology)</term><term>Tourette Syndrome (diagnosis)</term><term>Tourette Syndrome (drug therapy)</term><term>Tourette Syndrome (physiopathology)</term><term>Tremor (diagnosis)</term><term>Tremor (drug therapy)</term><term>Tremor (physiopathology)</term><term>Warfarin (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Phenindione</term><term>Phenprocoumon</term><term>Warfarin</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Antiphospholipid Syndrome</term><term>Cerebral Infarction</term><term>Dyskinesias</term><term>Lupus Erythematosus, Systemic</term><term>Movement Disorders</term><term>Myoclonus</term><term>Sneddon Syndrome</term><term>Spinocerebellar Degenerations</term><term>Tics</term><term>Tourette Syndrome</term><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electroencephalography</term><term>Electromyography</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Antiphospholipid Syndrome</term><term>Cerebral Infarction</term><term>Dyskinesias</term><term>Lupus Erythematosus, Systemic</term><term>Movement Disorders</term><term>Myoclonus</term><term>Sneddon Syndrome</term><term>Spinocerebellar Degenerations</term><term>Tics</term><term>Tourette Syndrome</term><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term><term>Frontal Lobe</term><term>Occipital Lobe</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Antiphospholipid Syndrome</term><term>Brain</term><term>Cerebral Infarction</term><term>Dyskinesias</term><term>Frontal Lobe</term><term>Lupus Erythematosus, Systemic</term><term>Movement Disorders</term><term>Myoclonus</term><term>Occipital Lobe</term><term>Sneddon Syndrome</term><term>Spinocerebellar Degenerations</term><term>Tics</term><term>Tourette Syndrome</term><term>Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Diagnosis, Differential</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Middle Aged</term><term>Neuropsychological Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Movement disorders have only rarely been reported in association with antiphospholipid syndrome (APS). In such cases, chorea is the most common disorder observed, with occasional reports of hemidystonia, Parkinsonism, and hemiballism. We report here on 3 cases of APS (3 women ages 16, 46, and 56 years) who presented with movement disorders, including tics, tremor, myoclonus, and a corticobasal syndrome, never or rarely reported in association with this disease. Mild executive dysfunction was observed in all 3 patients. We also report the successful treatment of two of these patients with mild oral anticoagulation (INR 2-3). Movement disorders in APS seem more clinically heterogeneous than previously thought. Oral anticoagulation should be considered in the treatment of movement disorders associated with APS.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16538618</PMID><DateCreated><Year>2006</Year><Month>08</Month><Day>28</Day></DateCreated><DateCompleted><Year>2006</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Atypical movement disorders in antiphospholipid syndrome.</ArticleTitle><Pagination><MedlinePgn>944-9</MedlinePgn></Pagination><Abstract><AbstractText>Movement disorders have only rarely been reported in association with antiphospholipid syndrome (APS). In such cases, chorea is the most common disorder observed, with occasional reports of hemidystonia, Parkinsonism, and hemiballism. We report here on 3 cases of APS (3 women ages 16, 46, and 56 years) who presented with movement disorders, including tics, tremor, myoclonus, and a corticobasal syndrome, never or rarely reported in association with this disease. Mild executive dysfunction was observed in all 3 patients. We also report the successful treatment of two of these patients with mild oral anticoagulation (INR 2-3). Movement disorders in APS seem more clinically heterogeneous than previously thought. Oral anticoagulation should be considered in the treatment of movement disorders associated with APS.</AbstractText><CopyrightInformation>(c) 2006 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Nee-Kong</ForeName><Initials>NK</Initials></Author><Author ValidYN="Y"><LastName>Mir</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Niall P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash P</ForeName><Initials>KP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5M7Y6274ZE</RegistryNumber><NameOfSubstance UI="D010630">Phenindione</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q08SIO485D</RegistryNumber><NameOfSubstance UI="D010644">Phenprocoumon</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016736">Antiphospholipid Syndrome</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002544">Cerebral Infarction</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020820">Dyskinesias</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004576">Electromyography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005625">Frontal Lobe</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008180">Lupus Erythematosus, Systemic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009207">Myoclonus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009778">Occipital Lobe</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010630">Phenindione</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010644">Phenprocoumon</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018860">Sneddon Syndrome</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013132">Spinocerebellar Degenerations</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020323">Tics</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014859">Warfarin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20842</ArticleId><ArticleId IdType="pubmed">16538618</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002D33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16538618
|texte= Atypical movement disorders in antiphospholipid syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16538618" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |